Importantly, we analyzed the survival difference between the altered and unaltered group of KCC2 (SLC12A5) and NKCC1 (SLC12A2) among 10,967 pan-cancer patients (Figure 8C), including disease-specific survival (DSS), PFS, and OS. Here, SLC12A2 is linked to cancer.